Based on REDEFINE trial populations and the NDA submission terms, expected eligibility criteria are: BMI 30 , or BMI 27 with at least one weight-related condition such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea Adults 18 years or older Not pregnant or breastfeeding Contraindications will likely include: personal or family history of MTC or MEN 2 syndrome, prior serious allergic reaction to semaglutide or cagrilintide, and active pancreatitis
casei Zhang slows the progression of acute and chronic kidney disease
doi: 10.3389/fimmu.2025.1663258 115 LiuYWangJLuoSZhanYLuQ
Give the dissolution process adequate time
Nabi R, Alvi SS, Shah A, Chaturvedi CP, Iqbal D, Ahmad S, et al
PMID 19891010